YKYong-Seok Kim

Yong-Seok Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong-Seok Kim has a total of 166 co-authors. Here are the top co-authors by number of shared publications:

  • Heung Kyu Park

    Department of Surgery Breast Cancer Center, Gil Medical Center of Gachon University, Incheon, Republic of Korea

    3 shared publications
  • Jeong-Soo Kim

    Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Surg, 222 Banpo Daero, Seoul, South Korea

    3 shared publications
  • Hoon Choi

    Department of Surgery, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea

    2 shared publications
  • Hye Sung Won

    Division of Medical Oncology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

    2 shared publications
  • Hyun Kyu Kim

    2 shared publications
  • Jiyoung Rhu

    Department of Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    Large Language Model Versus Manual Review for Clinical Data Curation in Breast Cancer: Retrospective Comparative Study

    by Young-Joon Kang, Hocheol Lee, Jae Pak Yi, Hyobin Kim, Chang Ik Yoon, Jong Min Baek, Yong-Seok Kim, Ye Won Jeon, Jiyoung Rhu, Su Hyun Lim, et al.

    Background: Manual review of electronic health records for clinical research is labor-intensive and prone to reviewer-dependent variations. Large language models (LLMs) offer potential for automated clinical data extraction; however, their feasibility in surgical oncology remains underexplored. Objective: This study aimed to evaluate the feasibility and accuracy of LLM-based processing compared with manual physician review for extracting clinical data from breast cancer records. Methods: We conducted a retrospective comparative study analyzing breast cancer records from 5 academic hospitals (January 2019-December 2019). Two data extraction pathways were compared: (1) manual physician review with direct electronic health record access (group 1: 1366/3100, 44.06%) and (2) LLM-based processing using Claude 3.5 Sonnet (Anthropic) on deidentified data automatically extracted through a clinical data warehouse platform (group 2: 1734/3100, 55.94%). The automated extraction system provided prestructured, deidentified data sheets organized by clinical domains, which were then processed by the LLM. The LLM prompt was developed through a 3-phase iterative process over 2 days. Primary outcomes included missing value rates, extraction accuracy, and concordance between groups. Secondary outcomes included comparison with the Korean Breast Cancer Society national registry data, processing time, and resource use. Validation involved 50 stratified random samples per group (900 data points each), assessed by 4 breast surgical oncologists. Statistical analysis included chi-square tests, 2-tailed t tests, Cohen κ, and intraclass correlation coefficients. The accuracy threshold was set at 90%. Results: The LLM achieved 90.8% (817) accuracy in validation analysis. Missing data patterns differed between groups: group 2 showed better lymph node documentation (missing: 152/1734, % vs 294/1366, %) but higher missing rates for cancer staging (211/1734, 12.17% vs 43/1366, 3.15%). Both groups demonstrated similar breast-conserving surgery rates (1107/1734, 84% vs 868/1366, %). Processing efficiency differed substantially: LLM processing required 12 days with 2 physicians versus 7 months with 5 physicians for manual review, representing a 91% reduction in physician hours (96 h vs 1025 h). The LLM group captured significantly more survival events (41 vs 11; P =.002). Stage distribution in the LLM group aligned better with national registry data (Cramér V=0.03 vs 0.07). Application programming interface costs totaled US $260 for 1734 cases (US $0.15 per case). Conclusions: LLM-based curation of automatically extracted, deidentified clinical data demonstrated comparable effectiveness to manual physician review while reducing processing time by 95% and physician hours by 91%. This 2-step approach—automated data extraction followed by LLM curation—addresses both privacy concerns and efficiency needs. Despite limitations in integrating multiple clinical events, this methodology offers a scalable solution for clinical data extraction in oncology research. The 90.8% accuracy rate and superior capture of survival events suggest that combining automated data extraction systems with LLM processing can accelerate retrospective clinical research while maintaining data quality and patient privacy.


  • Open Access

    P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells

    by DER Sheng Sun, Jung-Sook Yoon, Yong-Seok Kim, Hye Sung Won

    Background/Aim: Interferon-induced trans-membrane protein 1 (IFITM1) is known to be involved in breast cancer progression. We aimed to investigate its role in estrogen receptor (ER)-positive breast cancer cells with wild-type p53 and tamoxifen-resistant breast cancer cells. Materials and Methods: The ER-positive breast cancer cell lines, MCF-7 with wild-type p53 and T47D with mutant p53, were used. We established an MCF-7-derived tamoxifen-resistant cell line (TamR) by long-term culture of MCF-7 cells with 4-hydroxytamoxifen. Results: IFITM1 inhibition in MCF-7 cells significantly decreased cell growth and migration. MCF-7 cells with suppression of IFITM1 using siRNA or ruxolitinib showed reduced cell viability after tamoxifen treatment compared with that in the control MCF-7 cells. Unexpectedly, mRNA and protein levels of IFITM1 were decreased in TamR cells compared with those in MCF-7 cells. TamR cells with suppression of IFITM1 using siRNA or ruxolitinib showed no change in cell viability after treatment with tamoxifen. P53 knockdown using siRNA reduced the mRNA levels of IRF9 and increased mRNA and protein levels of SOCS3 in MCF-7 cells, suggesting that loss or mutation of p53 can affect the induction of IFITM1 via the JAK/STAT signaling pathway in breast cancer. Furthermore, MCF-7 cells with p53 knockdown using siRNA showed no decrease in cell viability after tamoxifen treatment or IFITM1 inhibition, indicating that p53 status may be important for cell death after tamoxifen treatment or IFITM1 inhibition. Conclusion: IFITM1 inhibition may enhance the sensitivity to tamoxifen based on p53-dependent enhancement of IFN signaling in wild-type p53, ER-positive breast cancer cells.


  • Open Access

    Subcutaneous implantation of thyroid carcinoma and benign tissue after thyroidectomy: report on two cases and review of the current literature

    by Yongseon Kim, Juneyoung Ahn, Yong-Seok Kim

    Background: Subcutaneous implantation of thyroid tissue after thyroidectomy is a rare occurrence involving both benign and malignant thyroid tissue. Clinically, subcutaneous implantation of thyroid tissue can be challenging to diagnose. We present two cases of subcutaneous implantation of thyroid tissue following thyroidectomy and discuss the differential diagnosis, clinicopathological characteristics, and the possible mechanism of implantation. Case Description: A 35-year-old woman (age in 2009) who underwent total thyroidectomy in 2009 whose histopathological examination revealed a nodular hyperplasia and lymphocytic thyroiditis complained of palpable mass in her neck 10 years after operation and underwent excision. Follicular adenoma was confirmed in histopathological results. A 58-year-old woman (age in 2010) who underwent lobectomy in 2010 for nodular hyperplasia had a 6 cm sized huge mass in her anterior neck 9 years after operation. Anterior neck mass excision was done and poorly differentiated carcinoma was confirmed in histopathological results. The patient showed no sign of recurrence after 3 years follow-up. Conclusions: Subcutaneous implantation of benign thyroid tissue or thyroid cancer can occur after thyroidectomy. Minimizing the likelihood of subcutaneous implantation requires careful consideration of various factors at every stage of the surgical procedure. Surgeons should be aware of this potential long-term complication that can occur in both conventional thyroidectomy and remote access surgery, effectively communicate and provide appropriate guidance to their patients, and try to avoid seeding of both malignant and benign thyroid tissue.


  • Open Access

    Predictive biological factors for late survival in patients with HER2-positive breast cancer

    by Young-Joon Kang, Se Jeong Oh, Soo Youn Bae, Eun-Kyu Kim, Young-Jin Lee, Eun Hwa Park, Joon Jeong, Heung Kyu Park, Young Jin Suh, Yong-Seok Kim

    The human epidermal growth factor receptor-2 (HER2) enriched subtype of breast cancer is associated with early recurrence, mostly within 5 years. However, anti-HER2 therapies have improved outcomes and their benefits persist in the long term. This study aimed to determine predictive factors for late survival in patients with HER2-positive breast cancer. We analyzed 20,672 patients with HER2-positive stage I–III breast cancer. The patients were divided into two groups based on a follow-up period of 60 months. The multivariate analysis of factors associated with poor overall survival included old age, advanced pathologic tumor size stage (pT), advanced pathologic regional lymph node stage (pN), high histological grade, presence of lymphatic and vascular invasion, and HR-negative status within 60 months. In the breast cancer-specific survival (BCSS) of the > 60 months follow-up group, the hazard ratios (HRa) based on pN-negative were 3.038, 3.722, and 4.877 in pN1 (p = 0.001), pN2 (p < 0.001), and pN3 (p < 0.001), respectively. Only pT4 level was statistically significant in the pT group (HRa, 4.528; p = 0.007). Age (HRa, 1.045, p < 0.001) and hormone receptor-positive status (HRa, 1.705, p = 0.022) were also associated to worse BCSS. Although lymphatic invasion was not significantly associated with BCSS, there was a tendency toward a relationship (p = 0.079) with worse BCSS. In HER2-positive breast cancer patients, node status had a more significant relationship with long-term prognosis than T stage. Patients with HER2-positive breast cancer who have T4 or node-positive should be considered for clinical observation and education beyond 5 years.


  • Open Access

    Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer

    by Yong-Seok Kim, Der Sheng Sun, Juneyoung Ahn, Yongseon Kim, Jung-Sook Yoon, Hye Sung Won

    We aimed to compare gene expression in primary tumors of patients with recurrence and nonrecurrence to gain insight into the biology of high-risk HER2-positive early breast cancer. Patients who underwent curative resection and received adjuvant trastuzumab for HER2-positive early breast cancer were evaluated. Gene expression analyses were performed using NanoString Technologies’ nCounter Breast Cancer 360 Panel. PAM50 intrinsic subtypes and Breast Cancer Signatures including tumor inflammation signature (TIS) were evaluated. Of 247 patients, 28 (11.3%) had recurrence at a median follow-up of 54.2 months. Patients with pathological stage III, tumor size > 5 cm, axillary lymph node metastases, and hormone receptor-negativity were more frequently observed in the recurrent group compared with the nonrecurrent group. In patients with recurrence, seven genes were upregulated significantly, including WNT11, HAPLN1, FGF10, BBOX1, CXADR, NDP, and EREG, and two genes were downregulated, including CXCL9 and GNLY. TIS score was significantly lower in patients with recurrence compared with controls without recurrence. These findings suggest that activation of oncogenic signaling pathways related to cell proliferation, adhesion, cancer stemness, and noninflamed tumor microenvironment are associated with the risk of recurrence in early stage, HER2-positive breast cancer.


  • Top Cited Papers
    Open Access

    Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society

    by Hye Sung Won, Juneyoung Ahn, Yongseon Kim, Jin Sung Kim, Jeong-Yoon Song, Hong-Kyu Kim, Jeeyeon Lee, Heung Kyu Park, Yong-Seok Kim

    Background: There is an increasing interest in HER2-low breast cancer with promising data from clinical trials using novel anti-HER2 antibody–drug conjugates. We explored the differences in clinicopathological characteristics and survival outcomes between HER2-low and HER2-IHC 0 breast cancer. Methods: Using nationwide data from the Korean Breast Cancer Registry between 2006 and 2011, 30,491 patients with stages I to III breast cancer were included in the analysis: 9,506 (31.2%) in the HER2-low group and 20,985 (68.8%) in the HER2-IHC 0 group. Kaplan–Meier and Cox proportional hazards regression survival analysis were used to compare breast cancer-specific survival between the two groups. Results: HER2-low breast cancer was more frequent in patients with hormone receptor-positive breast cancer than in those with triple-negative breast cancer. In patients with hormone receptor-positive breast cancer, HER2-low breast cancer was associated with fewer T4 tumors, higher histological grade, and a negative lymphatic invasion. In patients with triple-negative breast cancer, HER2-low breast cancer was associated with a high lymph node ratio and positive lymphatic invasion. HER2-low breast cancer was significantly associated with a lower Ki-67 labeling index. No significant difference was observed in overall survival between the two groups. HER2-low breast cancer showed significantly better breast cancer-specific survival than HER2-IHC 0 breast cancer, regardless of the hormone receptor status. In multivariate analysis, the impact of low HER2 expression on breast cancer-specific survival was significant only in triple-negative breast cancer (HRs, 0.68; 95% CI, 0.49–0.93; P = 0.019). Conclusions: These findings suggest that the biology and clinical impact of low HER2 expression can differ according to the hormone receptor status and support the need for further investigation on the understanding of the biology of HER2-low breast cancer.


  • Open Access

    Viscum album extract (Helixor-M) treatment for thoracic duct injury after modified radical neck dissection: a case report

    by Chai-Won Kim, Jeong-Soo Kim, Ae-Hee Lee, Yong-Seok Kim

    Chyle leakage after modified radical neck dissection is a rare condition that could be occasionally life-threatening if untreated. We report the first case of successful management of a thoracic duct injury using Viscum album extract (Helixor-M). A 54-year-old woman diagnosed with papillary thyroid cancer of the right lobe of the thyroid with metastasis to cervical lymph node levels II-VI, bilaterally, underwent total thyroidectomy and modified radical neck dissection. Three days postoperatively, the surgical team identified a thoracic duct injury due to drainage of chyle from the Jackson-Pratt drain inserted in the right side of the patient`s neck. Various medical treatments (octreotide, withdrawal of enteral feeding, and total parenteral nutrition) and surgical treatments [lymphatic ligation of cervical lymph node level IV and negative pressure wound therapy (vacuum-assisted closure)] were performed, but the drainage persisted. Viscum album extract (Helixor-M) was then injected through the drain. The dose of Viscum album extract was increased while being cautious of its adverse effects, such as nausea, vomiting, erythema, induration at the injection site, and flu-like symptoms. The injection was effective in stopping the drainage and the patient’s condition improved, without recurrence. The patient was discharged on the 64th postoperative day without any further complications. Our results suggest that treatment of thoracic duct injury after neck surgery with Viscum album extract (Helixor-M) may be a novel, less invasive alternative approach to treat cases resistant to standard treatments.


  • Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society

    by Young-Joon Kang, Se Jeong Oh, Hoon Choi, Shijin Cho, Chang-Hyun Shin, Chaiwon Kim, Joohyun Woo, JungSun Lee, Heung Kyu Park, Han-Byoel Lee, et al.

    Purpose The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials. The objective of this study was to evaluate the survival of patients in a monoethnic group diagnosed with T1b lymph node-negative breast cancer depending on HER2 status. Methods We analyzed 3110 patients with T1bN0M0 breast cancer whose data were deposited into the Korean Breast Cancer Society Registry database between 2000 and 2009. Overall survival (OS) and breast cancer-specific survival (BCSS) were compared according to HER2 status. Results Among all patients, 494 (15.9%) had HER2-positive breast cancer. At a mean follow-up of 93 months, 108 deaths and 86 breast cancer-specific deaths were noted among all patients. There was no significant difference in OS between the HER2-negative and HER2-positive groups (p = 0.103). The same result was observed for BCSS. However, in the subgroup of estrogen receptor (ER)-positive women, HER2-negative patients had a better BCSS prognosis than HER2-positive patients (p = 0.025). Multivariate analysis also indicated a significant difference in BCSS in the ER-positive subgroup (HR 2.60; 95% CI 1.15–5.87; p = 0.021). Conclusion This study analyzed a large nationwide and monoethnic cohort and found a significant difference only in BCSS in the ER-positive subgroup according to HER2 status. Anti-HER2 therapy may be considered in HER2-positive and ER-positive patients with small, node-negative breast cancer.


  • Open Access

    Impact of the COVID-19 Pandemic on the Diagnosis and Surgery of Breast Cancer: A Multi-Institutional Study

    by Young-Joon Kang, Jong Min Baek, Yong-Seok Kim, Ye Won Jeon, Tae-Kyung Yoo, Jiyoung Rhu, Chang-Hyun Shin, Shijin Cho, Hoon Choi, Se Jeong Oh

    Kang YJ, et al. J Breast Cancer. 2021 Dec;24:e55. https://doi.org/10.4048/jbc.2021.24.e55